Role of circulating microRNAs in the development of hypertrophic cardiomyopathy: an analysis of current research
https://doi.org/10.15829/1728-8800-2025-4562
EDN: UVEVWK
Abstract
Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease and a leading cause of sudden cardiac death in young adults. Recently, an increasing number of studies have been published examining the role of microRNAs in the regulation of key pathological processes in HCM, such as myocardial fibrosis, cardiomyocyte hypertrophy, and cardiac remodeling. The aim of this review is to analyze recent original studies analyzing the potential of circulating microRNAs as biomarkers for diagnosis and risk assessment in patients with HCM.
About the Authors
O. V. Kulikova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Petroverigsky Lane, 10, bld. 3, Moscow, 101990
A. V. Kiseleva
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Petroverigsky Lane, 10, bld. 3, Moscow, 101990
R. P. Myasnikov
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Petroverigsky Lane, 10, bld. 3, Moscow, 101990
A. N. Meshkov
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Petroverigsky Lane, 10, bld. 3, Moscow, 101990
O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Petroverigsky Lane, 10, bld. 3, Moscow, 101990
References
1. Bokeria lA, Shlyakhto EV, Gabrusenko SA, et al. 2025 Clinical practice guidelines for Hypertrophic cardiomyopathy. Russian Journal of Cardiology. 2025;30(5):6387. (In Russ.) doi:10.15829/1560-4071-2025-6387.
2. Goff ZD, Calkins H. Sudden death related cardiomyopathies — Hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2019;62: 212-16. doi:10.1016/j.pcad.2019.04.001.
3. O’Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35:2010-20. doi:10.1093/eurheartj/eht439.
4. Sohel MH. Extracellular/circulating MicroRNAs: Release mechanisms, functions and challenges. Achiev Life Sci. 2016;10: 175-86. doi:10.1016/j.als.2016.11.007.
5. Ntelios D, Georgiou E, Alexouda S, et al. A critical approach for successful use of circulating microRNAs as biomarkers in cardiovascular diseases: the case of hypertrophic cardiomyopathy. Heart Fail Rev. 2022;27:281-94. doi:10.1007/s10741-021-10084-y.
6. Chiti E, Paolo MD, Turillazzi E, Rocchi A. MicroRNAs in Hypertrophic, Arrhythmogenic and Dilated Cardiomyopathy. Diagnostics. 2021;11:1720. doi:10.3390/diagnostics11091720.
7. Burnasheva GA, Myasnikov RP, Kulikova OV, et al. Prognostic value of morphological, biochemical, molecular markers of fibrosis in patients with hypertrophic cardiomyopathy. Cardiovascular Therapy and Prevention. 2023;22(12):3839. (In Russ.) doi:10.15829/1728-8800-2023-3839.
8. Huang D, Chen Z, Wang J, et al. MicroRNA-221 is a potential biomarker of myocardial hypertrophy and fibrosis in hypertrophic obstructive cardiomyopathy. Biosci Rep. 2020;40:BSR20191234. doi:10.1042/BSR20191234.
9. Lombardi M, Lazzeroni D, Benedetti G, et al. Plasmatic and myocardial microRNA profiles in patients with Hypertrophic Cardiomyopathy. Clin Transl Med. 2021;11:e435. doi:10.1002/ctm2.435.
10. Thottakara T, Lund N, Krämer E, et al. A novel miRNA screen identifies miRNA-4454 as a candidate biomarker for ventricular fibrosis in patients with hypertrophic cardiomyopathy. Biomolecules. 2021;11(11):1718. doi:10.3390/biom11111718.
11. Baulina N, Pisklova M, Kiselev I, et al. Circulating miR-499a-5p is a potential biomarker of MYH7-associated hypertrophic cardiomyopathy. Int J Mol Sci. 2022;23:3791. doi:10.3390/ijms23073791.
12. Feng W, Han S. LncRNA ADAMTS9-AS1/circFN1 competitively binds to miR-206 to elevate the expression of ACTB, thus inducing hypertrophic cardiomyopathy. Oxid Med Cell Longev. 2022;2022(1):1450610. doi:10.1155/2022/1450610.
13. Lin L-R, Hu X-Q, Lu L-H, et al. MicroRNA expression profiles in familial hypertrophic cardiomyopathy with myosin-binding protein C3 (MYBPC3) gene mutations. BMC Cardiovasc Disord. 2022;22: 278. doi:10.1186/s12872-022-02714-6.
14. Liang LW, Hasegawa K, Maurer MS, et al. Comprehensive transcriptomics profiling of MicroRNA reveals plasma circulating biomarkers of hypertrophic cardiomyopathy and dysregulated signaling pathways. Circ Heart Fail. 2023;16:e010010. doi:10.1161/CIRCHEARTFAILURE.122.010010.
15. Pisklova MV, Baulina NM, Kiselev IS, et al. The levels of certain circulating microRNAs in hypertrophic cardiomyopathy are associated with echocardiographic parameters. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(4):302-8. (In Russ.) doi:10.26442/00403660.2023.04.202162.
16. Sonsöz MR, Yilmaz M, Cevik E, et al. Circulating Levels of MicroRNAs in Hypertrophic Cardiomyopathy: The Relationship With Left Ventricular Hypertrophy, Left Atrial Dilatation and Ventricular Depolarisation-Repolarisation Parameters. Heart Lung Circ. 2021;31:199-206. doi:10.1016/j.hlc.2021.04.019.
17. Sucharov CC, Neltner B, Pietra AE, et al. Circulating MicroRNAs identify early phenotypic changes in sarcomeric hypertrophic cardiomyopathy. Circ Heart Fail. 2023;16:e010291. doi:10.1161/CIRCHEARTFAILURE.122.010291.
18. Foglieni C, Lombardi M, Lazzeroni D, et al. Myosins and MyomiR Network in Patients with Obstructive Hypertrophic Cardiomyopathy. Biomedicines. 2022;10:2180. doi:10.3390/biomedicines10092180.
19. Angelopoulos A, Oikonomou E, Antonopoulos A, et al. Expression of Circulating miR-21 and -29 and their Association with Myocardial Fibrosis in Hypertrophic Cardiomyopathy. Curr Med Chem. 2024; 31:3987-96. doi:10.2174/0109298673286017240103073130.
20. Guo L, Cai Y, Wang B, et al. Characterization of the circulating transcriptome expression profile and identification of novel miRNA biomarkers in hypertrophic cardiomyopathy. Eur J Med Res. 2023;28:205. doi:10.1186/s40001-023-01159-7.
21. Karakikes I, Chaanine AH, Kang S, et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc. 2013;2:e000078. doi:10.1161/JAHA.113.000078.
22. Wang Y, Pan W, Bai X, et al. microRNA-454-mediated NEDD4-2/TrkA/cAMP axis in heart failure: Mechanisms and cardioprotective implications. J Cell Mol Med. 2021;25:5082-98. doi:10.1111/jcmm.16491.
23. Pisklova MV, Baulina NM, Kiselev IS, Favorova OO. MicroRNA-499a in heart diseases: prospects for use in diagnostics. A review. Terapevticheskii Arkhiv (Ter Arkh.). 2025;97(4):353-9. (In Russ.) doi:10.26442/00403660.2025.04.203161.
24. Chan S-F, Cheng H, Goh KK-R, Zou R. Preanalytic Methodological Considerations and Sample Quality Control of Circulating miRNAs. J Mol Diagn. 2023;25:438-53. doi:10.1016/j.jmoldx.2023.03.005.
25. Maron BJ, Rowin EJ, Maron MS. Hypertrophic cardiomyopathy: New concepts and therapies. Annu Rev Med. 2022;73:363-75. doi:10.1146/annurev-med-042220-021539.
Supplementary files
What is already known about the subject?
- Hypertrophic cardiomyopathy is a disease with a high risk of sudden cardiac death.
- Circulating microRNAs are potential biomarkers of hypertrophic cardiomyopathy.
What might this study add?
- Current studies investigating the profile of circulating microRNAs in patients with hypertrophic cardiomyopathy are characterized by significant methodological heterogeneity, making it difficult to directly compare data and draw definitive conclusions.
Review
For citations:
Kulikova O.V., Kiseleva A.V., Myasnikov R.P., Meshkov A.N., Drapkina O.M. Role of circulating microRNAs in the development of hypertrophic cardiomyopathy: an analysis of current research. Cardiovascular Therapy and Prevention. 2025;24(10):4562. (In Russ.) https://doi.org/10.15829/1728-8800-2025-4562. EDN: UVEVWK
Views:
440
Email this article 
